Innovative Strategies for Parasite Management: Integrating Drug Resistance Studies and Novel Therapeutic Targets

Dunia Abed Hussein  Al-Tikrity

doi:10.17605/cajmns.v6i4.2885

Dunia Abed Hussein Al-Tikrity Biology Department, College Education for Woman, Tikrit University, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i4.2885

Keywords: Morphological Feature Analysis, Drug Resistance Simulation, Parasitic Diseases, Microscopic Image Processing, Interpretable Diagnostics

Abstract

Parasitic diseases represent a central health burden to many parts of the world, especially in the resource-limited setting. The increased rates of infected populations by drug-resistant strains of parasites indicate the essential demand of new interpretable techniques of parasite control. This paper presents a two-modality system which combines morphological feature analysis with modeling synthetic drug resistance. Based on applying more than 34,000 high-resolution, microscopic parasite and host cell images collected in eight different parasite and host cell classes, five most important morphology characteristics, i.e. area, perimeter, circularity, aspect, and intensity were extracted and analyzed statistically. An in-silico drug resistance profile of four antiparasitic drugs (Chloroquine, Amphotericin B, Suramin, and Metronidazole) was also established by estimating literatures-informed conclusions. Graphical representations, including the boxplot, heatmap, and pair plot, were used to identify some relationships between the structural characteristics and resistance patterns. Specific morphological profile was found in species such as Leishmania and Trypanosome as well as in increased simulated resisting levels. The innovation of the present work is that it has derived an explanatory, low-complexity model linking phenotypic image characterization with hypothetical drugs profiles that can be applied to parasite diagnostics--a method that has hitherto been uncharacteristic. The model is portable and affordable and provides the scalable solution to early resistance detection and morphological classification, which are most relevant in conditions when advanced molecular tools are not readily available.

References

S. Abaza, ‘Recent advances in identification of potential drug targets and development of novel drugs in parasitic diseases. Part I: drug resistance’, Parasitol. United J., vol. 14, no. 3, pp. 244–260, 2021.

A. C. Aguiar, L. R. F. de Sousa, C. R. S. Garcia, G. Oliva, and R. V. C. Guido, ‘New molecular targets and strategies for antimalarial discovery’, Curr. Med. Chem., vol. 26, no. 23, pp. 4380–4402, 2019.

F. Altamura, R. Rajesh, C. M. C. Catta-Preta, N. S. Moretti, and I. Cestari, ‘The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets’, Drug Dev. Res., vol. 83, no. 2, pp. 225–252, 2022.

S. Alven and B. Aderibigbe, ‘Combination therapy strategies for the treatment of malaria’, Molecules, vol. 24, no. 19, p. 3601, 2019.

T. M. Belete, ‘Recent progress in the development of new antimalarial drugs with novel targets’, Drug Des. Devel. Ther., pp. 3875–3889, 2020.

J. Clegg, E. Soldaini, R. M. McLoughlin, S. Rittenhouse, F. Bagnoli, and S. Phogat, ‘Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies’, Front. Immunol., vol. 12, p. 705360, 2021.

A. N. Cowell and E. A. Winzeler, ‘Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections’, Genome Med., vol. 11, no. 1, p. 63, 2019.

M. Gopikrishnan, S. Haryini, and G. P. D. C, ‘Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: A comprehensive review’, J. Basic Microbiol., vol. 64, no. 5, p. 2300579, 2024.

S. Hendrickx, G. Caljon, and L. Maes, ‘Need for sustainable approaches in antileishmanial drug discovery’, Parasitol. Res., vol. 118, no. 10, pp. 2743–2752, 2019.

S. Hu, Z. Batool, X. Zheng, Y. Yang, A. Ullah, and B. Shen, ‘Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities’, J. Pharm. Anal., vol. 15, no. 1, p. 101084, 2025.

A. Kumar, Deepika, S. Sharda, and A. Avasthi, ‘Recent Advances in the Treatment of Parasitic Diseases: Current Status and Future’, Nat. Prod. Based Drug Discov. Against Hum. Parasites Oppor. Challenges, pp. 249–286, 2023.

S. Jain, U. Sahu, A. Kumar, and P. Khare, ‘Metabolic pathways of Leishmania parasite: Source of pertinent drug targets and potent drug candidates’, Pharmaceutics, vol. 14, no. 8, p. 1590, 2022.

M. A. Villamizar-Monsalve, J. López-Abán, B. Vicente, R. Peláez, and A. Muro, ‘Current drug strategies for the treatment and control of schistosomiasis’, Expert Opin. Pharmacother., vol. 25, no. 4, pp. 409–420, 2024.

M. Peng, F. Chen, Z. Wu, and J. Shen, ‘Endoplasmic reticulum stress, a target for drug design and drug resistance in parasitosis’, Front. Microbiol., vol. 12, p. 670874, 2021.

N. S. Tibon, C. H. Ng, and S. L. Cheong, ‘Current progress in antimalarial pharmacotherapy and multi-target drug discovery’, Eur. J. Med. Chem., vol. 188, p. 111983, 2020.

A. O. Olatunji, J. A. Olaboye, C. C. Maha, T. O. Kolawole, and S. Abdul, ‘Next-Generation strategies to combat antimicrobial resistance: Integrating genomics, CRISPR, and novel therapeutics for effective treatment’, Eng. Sci. & Technol. J., vol. 5, no. 7, pp. 2284–2303, 2024.

M. A. Shibeshi, Z. D. Kifle, and S. A. Atnafie, ‘Antimalarial drug resistance and novel targets for antimalarial drug discovery’, Infect. Drug Resist., pp. 4047–4060, 2020.

L. Wei et al., ‘Host-directed therapy, an untapped opportunity for antimalarial intervention’, Cell Reports Med., vol. 2, no. 10, 2021.

M. M. Ippolito, K. A. Moser, J.-B. B. Kabuya, C. Cunningham, and J. J. Juliano, ‘Antimalarial drug resistance and implications for the WHO global technical strategy’, Curr. Epidemiol. reports, vol. 8, no. 2, pp. 46–62, 2021.

X. Shao et al., ‘Novel therapeutic strategies for treating Pseudomonas aeruginosa infection’, Expert Opin. Drug Discov., vol. 15, no. 12, pp. 1403–1423, 2020.